Recruitment Target Reached | 招募人數達標
Thank you for your interest in participating. Our current recruitment target has been reached.
感謝您對參與本研究的興趣，但目前的招募人數已達標。
Vaccine allergy safety track (VAS-Track) to COVID-19
Experiences from other countries have shown that severe allergic reactions (anaphylaxis) to the novel COVID-19 vaccinations are occurring at an unprecedented rate. Albeit rare, these anaphylactic reactions often occur at the first dose after COVID-19 vaccinations and can be life-threatening. Therefore, COVID-19 vaccines are currently restricted from at-risk patients with a history of severe allergic reactions.
Utilising state-of-the-art clinical and laboratory allergy testing, HKU Department of Medicine will pilot the territory's first COVID-19 vaccine allergy protocol to study how to best facilitate at-risk patients to safely receive the COVID-19 vaccinations.
2019冠狀病毒病疫苗的過敏安全性追蹤研究
其他國家的經驗顯示，接種2019冠狀病毒病疫苗可引致嚴重過敏反應。雖然情況罕見，但這些嚴重過敏反應通常在完成接種第一針後出現，甚至可構成生命危險。因此，有嚴重過敏史的人士，現時被禁止接種2019冠狀病毒病疫苗。
透過最先進的臨床及實驗室過敏測試，港大醫學院內科學系將率先推行全港首個2019冠狀病毒病疫苗過敏研究，從而找出如何促進有過敏風險的人士，安全地接種2019冠狀病毒病疫苗的方法。
Participants Recruitment | 研究對象招募
You are eligible to join the study if you consent to allergy testing (skin and blood tests) AND meet the any of the following requirements:
-
History of reactions to multiple classes of drugs or anaphylaxis
-
History of anaphylaxis or at risk of anaphylaxis
-
Severe reactions after other allergens, e.g. drugs/foods/insects (especially injectables)
-
Severe reactions after other vaccines or prior COVID-19 vaccine
我們將招募同意接受過敏測試（檢查皮膚及血液），並且符合以下任一條件的患者為研究對象：
-
曾對多種藥物類別過敏或對藥物有嚴重過敏反應的病歷
-
有嚴重過敏史或風險
-
曾對其他致敏原有嚴重反應，例如藥物／食品／昆蟲（尤其是注射劑）
-
以往曾對其他疫苗或之前接種2019冠狀病毒病疫苗有嚴重反應
Enquiries | 聯絡研究團隊
For any enquiries, please contact Mr Li:
如有查詢，請聯絡：
- Telephone: +852 2255 2369
- Email: jimmy325@hku.hk